Cognitact Limited
Cognitact is a biotechnology company focused on the early detection of Alzheimer's Disease through an AI-powered multi-protein blood test called PlasmarkAD®. Their technology utilizes a proprietary machine learning algorithm that analyzes 22 multi-protein biomarkers from a simple blood draw to detect the risk of Alzheimer's disease with over 96% accuracy. The company leverages over 30 years of research data, exclusively licensed from a top-tier local university. Cognitact's approach enables early prevention, identification, and treatment by detecting pathological changes up to 15-20 years before clinical symptoms appear, capitalizing on the effectiveness of early-stage Alzheimer's medications. They have conducted clinical trials with over 1000 patients and validated their findings across multiple ethnicities. Cognitact aims to provide a crucial tool for proactive brain health management.
Cognitact Limited
Cognitact is a biotechnology company focused on the early detection of Alzheimer's Disease through an AI-powered multi-protein blood test called PlasmarkAD®. Their technology utilizes a proprietary machine learning algorithm that analyzes 22 multi-protein biomarkers from a simple blood draw to detect the risk of Alzheimer's disease with over 96% accuracy. The company leverages over 30 years of research data, exclusively licensed from a top-tier local university. Cognitact's approach enables early prevention, identification, and treatment by detecting pathological changes up to 15-20 years before clinical symptoms appear, capitalizing on the effectiveness of early-stage Alzheimer's medications. They have conducted clinical trials with over 1000 patients and validated their findings across multiple ethnicities. Cognitact aims to provide a crucial tool for proactive brain health management.